AbbVie | Pharmaceutical Research & Development

AbbVie's coronavirus response

Learn more

May 5, 2020 / Press Release

AbbVie Receives Health Canada Approval for the Combination of VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia

March 11, 2020 / Press Release

AbbVie announces new formulary listings for SKYRIZI^® in the treatment of moderate to severe plaque psoriasis

February 26, 2020 / Press Release

VENCLEXTA^® with Rituximab, a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL), now reimbursed in British Columbia

Stories

Advocating Against Pain: Philippa's Endometriosis Journey

Stories

Stronger Together: Mark’s journey with CLL

Stories

Standing up and advocating for cancer patients, caregivers, and survivors

Our approach to innovation builds on strong science combined with the drive to find solutions where the need is the greatest

Our Science

Pipeline

Advancing medicines with strong clinical performance in areas of great need

Focus Areas

Driving innovation across oncology, immunology, neuroscience and more

Careers

Work with us to turn world-class research into life-changing results

The people and the breakthroughs that are leading to long-lasting impact

Responsibility

7,200+

employees in Western Europe and Canada

PhRMA/Native Content project at Abbott Labs in Chicago, IL. Still photo by Kevin J. Miyazaki/Redux

Passionate about our work, responsible in our actions—we go beyond medicine to improve health care and our communities

Community

$5.1 billion

Invested in research and development in 2018

AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives

Our Company

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.